Information Provided By:
Fly News Breaks for April 16, 2019
Apr 16, 2019 | 06:03 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $33 from $25 after the company received FDA clearance to start a Phase II/III trial of wholly-owned ARO-AAT in Alpha-1 antitrypsin deficiency. The analyst increased his value for ARO-AAT and reiterates an Overweight rating on Arrowhead shares.
News For ARWR From the Last 2 Days
There are no results for your query ARWR